January, 2014. ORYZON, a biopharmaceutical company with a strong focus on epigenetics, has recently received the approval from the Spanish Medicines Agency (AEMPS) to initiate a Phase I/IIA first-in-man clinical trial of ORY-1001, a novel and highly selective LSD1 inhibitor, in patients with relapsed or refractory acute leukemia.
IDIFARMA collaborates with ORYZON providing the necessary pharmaceutical development services to bring a novel drug to the clinical phase (formulation and analytical development, GMP manufacturing of clinical batches, stability studies, primary and secondary packaging, quality control and batch release), leveraging our capabilities to handle high potency drugs and our experience in similar projects.
We want to thank ORYZON for trusting IDIFARMA for this project and we wish them the best during the clinical development of ORY-1001.
|Last Updated on Friday, 10 January 2014 13:01|